Low protein diet inhibits uric acid synthesis and attenuates renal damage in streptozotocin-induced diabetic rats

Journal of Diabetes Research

Volumn 2014, Issue , 2014, Pages

  Ran, Jianmin ^a   Ma, Jing ^a   Liu, Yan ^a   Tan, Rongshao ^a   Liu, Houqiang ^a   Lao, Gancheng ^a  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; STREPTOZOCIN; URIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; EPITHELIUM CELL; KIDNEY INJURY; MALE; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DIET; PROTEIN RESTRICTION; RAT; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINARY EXCRETION; VITAL SIGN; ALBUMINURIA; ANIMAL; BLOOD; CELL PROLIFERATION; CELL SIZE; DIET THERAPY; EXPERIMENTAL DIABETES MELLITUS; EXTRACELLULAR FLUID; HYPERGLYCEMIA; HYPERURICEMIA; KIDNEY; KIDNEY TUBULE; METABOLISM; PATHOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT; URINE;

ALBUMINURIA; ANIMALS; CELL PROLIFERATION; CELL SIZE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DIET, PROTEIN-RESTRICTED; EXTRACELLULAR FLUID; HYPERGLYCEMIA; HYPERURICEMIA; KIDNEY; KIDNEY TUBULES; MALE; MESANGIAL CELLS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; TUMOR NECROSIS FACTOR-ALPHA; URIC ACID;

EID: 84897500440     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2014/287536     Document Type: Article

References (42)

1. Reeves W. B., Rawal B. B., Abdel-Rahman E. M., Therapeutic modalities in diabetic nephropathy: future approaches. Open Journal of Nephrology 2012 2 2 5 18
2. Kostapanos M. S., Florentin M., Elisaf M. S., Fenofibrate and the kidney: an overview. European Journal of Clinical Investigation 2013 43 5 522 531
3. Kania D. S., Smith C. T., Nash C. L., Potential new treatments for diabetic kidney disease. Medical Clinics of North America 2013 97 1 115 134
4. Tseng C.-H., Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney International 2005 68 2 796 801 2-s2.0-23744490953 10.1111/j.1523-1755.2005.00459.x
5. Hovind P., Rossing P., Tarnow L., Johnson R. J., Parving H.-H., Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 2009 58 7 1668 1671 2-s2.0-67650242157 10.2337/db09-0014
6. Kosugi T., Nakayama T., Heinig M., Zhang L., Yuzawa Y., Sanchez-Lozada L. G., Roncal C., Johnson R. J., Nakagawa T., Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. The American Journal of Physiology-Renal Physiology 2009 297 2 F481 F488 2-s2.0-68049101366 10.1152/ajprenal.00092.2009
7. Siu Y.-P., Leung K.-T., Tong M. K.-H., Kwan T.-H., Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. The American Journal of Kidney Diseases 2006 47 1 51 59 2-s2.0-29244447160 10.1053/j.ajkd.2005.10.006
8. Momeni A., Shahidi S., Seirafian S., Taheri S., Kheiri S., Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iranian Journal of Kidney Diseases 2010 4 2 128 132 2-s2.0-77953162788
9. de Santo N. G., Perna A., Cirillo M., Low protein diets are mainstay for management of chronic kidney disease. Frontiers in Bioscience 2011 3 1432 1442 2-s2.0-80053121408
10. Rigalleau V., Raffaitin C., Gin H., Lasseur C., Chauveau P., Aparicio M., Combe C., The effect of a low-protein diet for diabetic nephropathy is underestimated. The American Journal of Clinical Nutrition 2009 89 4 1277 1278 2-s2.0-63649128600 10.3945/ajcn.2008.27123
11. Kosugi T., Heinig M., Nakayama T., Connor T., Yuzawa Y., Li Q., Hauswirth W. W., Grant M. B., Croker B. P., Campbell-Thompson M., Zhang L., Atkinson M. A., Segal M. S., Nakagawa T., Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. The American Journal of Pathology 2009 174 4 1221 1229 2-s2.0-65349142464 10.2353/ajpath.2009.080605
12. Aunapuu M., Roosaar P., Järveots T., Kurrikoff K., Kõks S., Vasar E., Arend A., Altered renal morphology in transgenic mice with cholecystokinin overexpression. Transgenic Research 2008 17 6 1079 1089 2-s2.0-54949157771 10.1007/s11248-008-9204-5
13. Kim S. M., Choi Y. W., Seok H. Y., Reducing serum uric acid attenuates TGF- β 1-induced Profibrogenic progression in type 2 diabetic nephropathy. Nephron Experimental Nephrology 2012 121 3-4 e109 e121
14. Eidi A., Eidi M., Esmaeili E., Antidiabetic effect of garlic (Allium sativum L.) in normal and streptozotocin-induced diabetic rats. Phytomedicine 2006 13 9-10 624 629 2-s2.0-33750507278 10.1016/j.phymed.2005.09.010
15. Sivakumar S., Palsamy P., Subramanian S. P., Impact of d-pinitol on the attenuation of proinflammatory cytokines, hyperglycemia-mediated oxidative stress and protection of kidney tissue ultrastructure in streptozotocin-induced diabetic rats. Chemico-Biological Interactions 2010 188 1 237 245 2-s2.0-77956174464 10.1016/j.cbi.2010.07.014
16. Villegas R., Xiang Y.-B., Elasy T., Xu W. H., Cai H., Cai Q., Linton M. F., Fazio S., Zheng W., Shu X.-O., Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men's health study. Nutrition, Metabolism and Cardiovascular Diseases 2012 22 5 409 416 2-s2.0-84860015738 10.1016/j.numecd.2010.07.012
17. Hak A. E., Choi H. K., Lifestyle and gout. Current Opinion in Rheumatology 2008 20 2 179 186 2-s2.0-40349097791 10.1097/BOR.0b013e3282f524a2
18. Xiong Z., Zhu C., Qian X., Serum uric acid is associated with dietary and lifestyle factors in elderly women in suburban Guangzhou in Guangdong province of south China. The Journal of Nutrition Health and Aging 2013 17 1 30 34
19. Shulten P., Thomas J., Miller M., Smith M., Ahern M., The role of diet in the management of gout: a comparison of knowledge and attitudes to current evidence. Journal of Human Nutrition and Dietetics 2009 22 1 3 11 2-s2.0-58549106611 10.1111/j.1365-277X.2008.00928.x
20. Frank H., Graf J., Amann-Gassner U., Bratke R., Daniel H., Heemann U., Hauner H., Effect of short-term high-protein compared with normal-protein diets on renal hemodynamics and associated variables in healthy young men. The American Journal of Clinical Nutrition 2009 90 6 1509 1516 2-s2.0-72749104164 10.3945/ajcn.2009.27601
21. Filipowicz R., Beddhu S., Optimal nutrition for predialysis chronic kidney disease. Advances in Chronic Kidney Disease 2013 20 2 175 180
22. Garneata L., Mircescu G., Effect of low-protein diet supplemented with keto acids on progression of chronic kidney disease. Journal of Renal Nutrition 2013 23 3 210 213
23. Bellizzi V., Low-protein diet or nutritional therapy in chronic kidney disease? Blood Purification 2013 36 1 41 46
24. Pedrini M. T., Levey A. S., Lau J., Chalmers T. C., Wang P. H., The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Annals of Internal Medicine 1996 124 7 627 632 2-s2.0-0029917114
25. Pan Y., Li L. G., Jin H. M., Guo L. L., Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. The American Journal of Clinical Nutrition 2008 88 3 660 666 2-s2.0-51749093569
26. Koya D., Haneda M., Inomata S., Suzuki Y., Suzuki D., Makino H., Shikata K., Murakami Y., Tomino Y., Yamada K., Araki S. I., Kashiwagi A., Kikkawa R., Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial. Diabetologia 2009 52 10 2037 2045 2-s2.0-69949179590 10.1007/s00125-009-1467-8
27. Sun Y. M., Su Y., Li J., Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochemical and Biophysical Research Communications 2013 433 4 359 361
28. Ninichuk V., Khandoga A. G., Segerer S., Loetscher P., Schlapbach A., Revesz L., Feifel R., Khandoga A., Krombach F., Nelson P. J., Schlöndorff D., Anders H.-J., The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. The American Journal of Pathology 2007 170 4 1267 1276 2-s2.0-34247892356 10.2353/ajpath.2007.060937
29. Tramonti G., Kanwar Y. S., Review and discussion of tubular biomarkers in the diagnosis and management of diabetic nephropathy. Endocrine 2013 43 3 494 503
30. Wada J., Makino H., Inflammation and the pathogenesis of diabetic nephropathy. Clinical Science 2013 124 3 139 152
31. Chow F. Y., Nikolic-Paterson D. J., Ozols E., Atkins R. C., Rollin B. J., Tesch G. H., Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney International 2006 69 1 73 80 2-s2.0-30944456936 10.1038/sj.ki.5000014
32. Baggiolini M., Chemokines and leukocyte traffic. Nature 1998 392 6676 565 568 2-s2.0-0032499260 10.1038/33340
33. Ninichuk V., Clauss S., Kulkarni O., Schmid H., Segerer S., Radomska E., Eulberg D., Buchner K., Selve N., Klussmann S., Anders H.-J., Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3′PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. The American Journal of Pathology 2008 172 3 628 637 2-s2.0-40449140901 10.2353/ajpath.2008.070601
34. Sayyed S. G., Ryu M., Kulkarni O. P., Schmid H., Lichtnekert J., Grüner S., Green L., Mattei P., Hartmann G., Anders H.-J., An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney International 2011 80 1 68 78 2-s2.0-79958836345 10.1038/ki.2011.102
35. Tufro A., Veron D., VEGF and podocytes in diabetic nephropathy. Seminars in Nephrology 2012 32 4 385 393
36. Bonnefond A., Saulnier P. J., Stathopoulou M. G., What is the contribution of two genetic variants regulating VEGF levels to type 2 diabetes risk and to microvascular complications? PLoS ONE 2013 8 2 e55921
37. Jalal D. I., Maahs D. M., Hovind P., Nakagawa T., Uric acid as a mediator of diabetic nephropathy. Seminars in Nephrology 2011 31 5 459 465 2-s2.0-80054055235 10.1016/j.semnephrol.2011.08.011
38. Martinon F., Pétrilli V., Mayor A., Tardivel A., Tschopp J., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006 440 7081 237 241 2-s2.0-32944468985 10.1038/nature04516
39. Anders H.-J., Muruve D. A., The inflammasomes in kidney disease. Journal of the American Society of Nephrology 2011 22 6 1007 1018 2-s2.0-79957773993 10.1681/ASN.2010080798
40. Grainger R., McLaughlin R. J., Harrison A. A., Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout. Rheumatology 2013 52 6 1018 1021
41. Omori H., Kawada N., Inoue K., Ueda Y., Yamamoto R., Matsui I., Kaimori J., Takabatake Y., Moriyama T., Isaka Y., Rakugi H., Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clinical and Experimental Nephrology 2012 16 4 549 556 2-s2.0-84856921649 10.1007/s10157-012-0609-3
42. Sánchez-Lozada L. G., Tapia E., Soto V., Ávila-Casado C., Franco M., Wessale J. L., Zhao L., Johnson R. J., Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron 2008 108 4 p69 p78 2-s2.0-43949115923 10.1159/000127837